View Post

Practicing Outside the Pharma Box in Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Dawn Fallik From: onclive.com When Martine Piccart, MD, PhD, was a child, she sometimes watched her father, a gynecologist, talk to his patients. She remembers his respect for them and their families and the way he communicated, focusing on the positive but not shying away from delivering bad news. “He always took the time to explain in detail not …

View Post

Gut microbe may promote breast cancers

In Clinical Trials by Barbara Jacoby

Source: Johns Hopkins Medicine From: eurekalert.org Short-term exposure to B. fragilis toxin leaves lasting impression in cells, increasing the risk for cancer A microbe found in the colon and commonly associated with the development of colitis and colon cancer also may play a role in the development of some breast cancers, according to new research from investigators with the Johns …

View Post

Evelo Biosciences, Inc. Presents Additional Interim Data from Phase 1/2 Clinical Trial of EDP1503 in Patients with Triple-Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: Evelo Biosciences, Inc. From: globenewswire.com –EDP1908 announced as clinical candidate in oncology after showing superior preclinical activity over EDP1503– –Interim clinical data for EDP1503 suggest potential of orally delivered SINTAX™ product candidates to activate systemic immunity– Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines which act in the small intestine …

View Post

GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers

In Clinical Trials by Barbara Jacoby

Source: GT Biopharma, Inc. From: prnewswire.com GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company’s proprietary NK cell engager (TriKE™) technology platform is pleased to announce the filing of U.S. and international patent applications, and the initiation of clinical development of TriKE™ therapy for the treatment of HER2+, HER3+ and HER2+/HER3+ heterodimer …

View Post

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788

In Clinical Trials by Barbara Jacoby

Source: Ambrx Inc. From: prnewswire.com – 74% ORR in the Phase 1 HER2-positive Breast Cancer Trial in China and 67% ORR in the Phase 1 HER2 Expressing Pan-tumor Trial in US/AU – Multiple Global Phase 2/3 Trials to Begin Early 2021 Ambrx Inc., a clinical-stage biopharmaceutical company focused on developing Precision Biologics using an expanded genetic code, provided a clinical …

View Post

Clinical Research Workshop looks at new ways to conceptualize clinical trials

In Clinical Trials by Barbara Jacoby

From: sabcsmeetingnews.org Clinical trials ultimately exist to improve patient care through development of new therapeutic agents and regimens that allow patients to live longer, healthier lives. However, clinical trials are not always designed with the patient participant in mind. Traditional trial design often does not include endpoints that capture patient goals or meaningful real-time participant feedback. In addition, traditional trial …

View Post

Pivotal Trials Lead to Transformative Approaches in HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Caroline Seymour From: onclive.com Four pivotal trials––KATHERINE, FeDeriCa, DESTINY-Breast01, and HER2CLIMB have not only amplified the armamentarium in HER2-positive breast cancer, but have illustrated the importance of neoadjuvant therapy, alternative administration methods, high-potency HER2-targeted therapy, and inclusion of all-comers with brain metastases in clinical trials. In a presentation during the 2020 Institutional Perspectives in Cancer webinar on breast cancer, …

View Post

New Pharma Trials Making Big Gains in Fight Against Triple-Negative Breast Cancer (TNBC)

In Clinical Trials by Barbara Jacoby

Source: USA News Group From: prnewswire.com Triple-negative Breast Cancer (TNBC) is a highly aggressive subtype that accounts for 15-20% of breast cancer cases and 25% of all breast cancer deaths. Unlike other breast cancers, treatments for TNBC involving hormone therapy and drugs that target HER2 protein are not helpful. With a dire need for new forms of treatment, there’s plenty of optimism …

View Post

The ‘Dynamic Space’ of HER2 Breast Cancer Treatment Strategies

In Clinical Trials by Barbara Jacoby

By: Rosana Gnanajothy, MD From: medpagetoday.com More evident than ever that one-size-fits-all approach is less likely to work Since the discovery of targeted therapy for HER2-positive breast cancer, the treatment algorithm has been modified by the advent of trials optimizing disease outcomes in high-risk disease, as well as trials exploring de-escalation strategies in lower-risk disease. A review by Danielle File, …

View Post

Clinical trials are vital for battling breast cancer

In In The News by Barbara Jacoby

From: local10.com In the battle against breast cancer, researchers and patients are teaming up to uncover new treatment options. When Debora Pedrini was diagnosed with early-stage triple-negative breast cancer in 2019 she didn’t expect to become part of a clinical trial. “When the clinical trial was offered to me, to be honest with you, it was a hurricane of feelings. …